ArticleJournal of clinical biochemistry and nutrition2025
Effect of chronic kidney disease and type 2 diabetes on plasma branched-chain amino acid cross-correlation: a novel metric for evaluating homeostasis.
Article in Journal of clinical biochemistry and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cross-correlations between plasma isoleucine (Ile), leucine (Leu), and valine (Val) concentrations are observed in healthy individuals (C group). A parallel shift in these correlations has been noted in patients with end-stage renal failure. To evaluate this shift, a novel b value metric is proposed to assess variations in individuals. Branched-chain amino acids (BCAAs) concentrations were analyzed in four groups: 69 healthy controls (C group), 97 patients with type 2 diabetes mellitus (T2DM), 63 patients with chronic kidney disease (CKD) not on hemodialysis (CKD), and 45 patients with CKD on hemodialysis (CKD-HD). The b value was calculated using the equation Y = aX + b, where coefficient a was derived from the regression line in the C, and each BCAA pair (X, Y) was substituted accordingly. The T2DM exhibited elevated BCAA levels; however, the b values for the (Ile, Leu) and (Ile, Val) pairs remained unchanged. The CKD and CKD-HD showed significant decreases in b values. In T2DM, increased BCAA levels followed the regression line observed in healthy individuals, whereas in CKD, decreased BCAA levels deviated from this pattern. The b value effectively detects changes in BCAA metabolism that are not captured by individual BCAA levels alone, serving as a novel indicator of altered BCAA metabolism and homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.